Amicus’ Crowley to lead gene therapy spinout after SPAC deal

After 16 years as Amicus’ CEO, John Crowley will lead the biotech’s new genetic medicines spinout as it merges with a SPAC to become a separate publicly traded entity with $400 million in funding.

Amicus Therapeutics Inc. (NASDAQ:FOLD) said Wednesday that its gene therapy unit will become Caritas Therapeutics Inc. and merge with Perceptive Advisors-backed special purpose acquisition company ARYA Sciences Acquisition Corp. IV (NASDAQ:ARYD). Amicus will hold 36% of Caritas’ equity following the transaction, and will be its largest shareholder...